Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression by Lara, Pedro C et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Radiation Oncology
Open Access Short report
Severe hypoxia induces chemo-resistance in clinical cervical tumors 
through MVP over-expression
Pedro C Lara*1,2, Marta Lloret1,2, Bernardino Clavo1,2, Rosa M Apolinario2, 
Luis Alberto Henríquez-Hernández2,3, Elisa Bordón2, Fausto Fontes2 and 
Agustín Rey2,4
Address: 1Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Spain, 2Canary Institute for Cancer Research 
(ICIC), Spain, 3Clinic Sciences Department of Las Palmas de Gran Canaria University (ULPGC), Spain and 4Pathology Department, Hospital 
Universitario de Gran Canaria Dr. Negrín, Spain
Email: Pedro C Lara* - plara@dcc.ulpgc.es; Marta Lloret - mllosae@hotmail.com; Bernardino Clavo - bclavar@gobiernodecanarias.org; 
Rosa M Apolinario - rapohid@gobiernodecanarias.org; Luis Alberto Henríquez-Hernández - lhenriquez@dcc.ulpgc.es; 
Elisa Bordón - elisarbr@gmail.com; Fausto Fontes - faustofontes@gmail.com; Agustín Rey - areylop@gobiernodecanarias.org
* Corresponding author    
Abstract
Oxygen molecule modulates tumour response to radiotherapy. Higher radiation doses are
required under hypoxic conditions to induce cell death. Hypoxia may inhibit the non-homologous
end-joining DNA repair through down regulating Ku70/80 expression. Hypoxia induces drug
resistance in clinical tumours, although the mechanism is not clearly elucidated. Vaults are
ribonucleoprotein particles with a hollow barrel-like structure composed of three proteins: major
vault protein (MVP), vault poly(ADP-ribose) polymerase, and telomerase associated protein-1 and
small untranslated RNA. Over-expression of MVP has been associated with chemotherapy
resistance. Also, it has been related to poor outcome in patients treated with radiotherapy alone.
The aim of the present study was to assess the relation of Major Vault Protein expression and
tumor hypoxia in clinical cervical tumors. MVP, p53 and angiogenesis, together with tumor
oxygenation, were determined in forty-three consecutive patients suffering from localized cervix
carcinoma. High MVP expression was related to severe hypoxia compared to low MVP expressing
tumors (p = 0.022). Tumors over-expressing MVP also showed increased angiogenesis (p = 0.003).
Besides it, in this study we show for the first time that severe tumor hypoxia is associated with high
MVP expression in clinical cervical tumors. Up-regulation of MVP by hypoxia is of critical relevance
as chemotherapy is currently a standard treatment for those patients. From our results it could be
suggested that hypoxia not only induces increased genetic instability, oncogenic properties and
metastatization, but through the correlation observed with MVP expression, another pathway of
chemo and radiation resistance could be developed.
Introduction
Growing cancers often acquire an increasing number of
genetic alterations. Such genetic changes, including chro-
mosomal translocation, gene amplification, intragenic
mutation, and gene silencing, are responsible for the acti-
vation of oncogenes and the inactivation of tumour-sup-
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pressor genes [1]. How cancer cells acquire genetic
instability remains unclear. Exposure of cells to adverse
conditions like hypoxia can lead to genome alterations,
enhancing the progression potential of tumor cells and
resistance to oncological treatments [1]. Hypoxia may
lead to conditions that causes increased spontaneous
damage to DNA or inhibit DNA repair processes, impair
DNA repair and cause tumor progression by altered p53
expression and increased angiogenesis [2,3]. Deregulation
of DNA repair pathways can contribute to the phenome-
non of hypoxia-induced genetic instability within the
tumor [4]. Hypoxia is measured in clinical tumors by sev-
eral techniques, including the Eppendorf polarographic
method [2,5]. In cervical cancer patients, hypoxia is com-
monly associated to a lesser response to treatment and
lower survival rates [6,7]. Hypoxic tumors have a signifi-
cant higher probability of relapse and death [7] and they
are resistant to chemotherapy [8]. Chemo-resistance
would be mediated by up-regulation of Major Vault Pro-
tein (MVP) through the Hypoxia-inducible factor 1 (HIF-
1) as shown in previously studies performed in vitro [9].
Hypoxia inhibits the non-homologous end joining
(NHEJ) DNA repair through down-regulating Ku70/80
expression, combined with increased angiogenesis and
altered p53 expression [2]. Cervical tumors over-express-
ing MVP also showed down-regulation of Ku70/80 and
BAX [10]. MVP over-expression has been associated with
a suppression of NHEJ repair, and subsequent genomic
instability [10]. These mechanisms would be responsible
for tumor progression in cervical carcinoma. Moreover,
MVP over-expression was associated to reduced long-term
local control in patients who achieved clinical complete
response to radio-chemotherapy [11]. The aim of the
present study was to assess the relation between the
expression of the Major Vault Protein and tumor hypoxia
in clinical cervical tumors.
Methods
Forty-three consecutive patients suffering from localized
cervix carcinoma were prospectively included in this study
from July 1997 to September 2001 [2]. Patients were diag-
nosed and treated by definitive radiation at the Hospital
Universitario Materno-Infantil, at the Hospital Universi-
tario Dr. Negrín and at the Hospital Universitario Insular
in Las Palmas de Gran Canaria (Spain). Written informed
consent was given previously. The study was approved by
the Research and Ethics Committee of our institution. The
mean age of the patients was 49.48 ± 12.79 years (median
48, range 29–81 years). Fourteen patients had stage I dis-
ease, 22 stage II and 7 stage III-IVA. MVP expression was
studied by immunohistochemistry in paraffin-embedded
4 μm sections incubated for the specific primary antibody
(MVP, Neomarkers CA, USA). A secondary biotinated
antibody (Dako Detection Kit, LSBA) was incubated for
30 minutes, and peroxidase-streptavidin-biotin complex
(Dako) was used afterward. Staining was revealed by
using diaminobenzidine tetra-hydrochloride substrate
(DAB Chromogen; Dako), followed by light counterstain-
ing with Harris hematoxylin as previously described [10].
Data of p53 and angiogenesis, estimated by CD-31 stain-
ing, were obtained from our files [2]. Paraffin-embedded
tissues from tumor biopsies were available from all
patients, and the most representative tumor block was
used for immunohistochemical analysis. Blocks were han-
dled as previously described and then incubated for the
specific secondary antibody (p53, Clon:DO-7, Novocastra
Laboratories Ltd., Newcastle upon Tyne, UK; CD-31
Clon:JC/70A, Dako, Carpintería, CA, USA) [2]. The pri-
mary antibody was omitted in one section as a negative
control in each set of slides. As a positive control, a strong
positive tumor for the oncoprotein was used. Tumor oxy-
genation was measured by an Eppendorf device following
standard criteria as previously described [2,12] using a
polarographic probe system "pO2 Histograph" (Eppen-
dorf AG, Hamburg, Germany). For each set of measure-
ments obtained from tumor, 200 single pO2 values were
recorded using at least 6 different electrode tracks. Tumor
hypoxia data were reanalyzed for detecting cases of severe
hypoxia and the percentage of pO2 values < 2.5 mmHg
were obtained from the pooled data and for each individ-
ual. Assessment of immunostaining or tumor oxygena-
tion result was blinded to knowledge of the clinical
outcome of the patient. Statistical analysis was performed
by SPSS 15.0 software.
Results
All immunohistochemical markers and hypoxia values
were known in all 43 cases (Figure 1). MVP expression was
considered low (negative/slightly positive) in 23 cases
and high (strongly positive) in 20 cases. Data of mean vas-
cular density (MVD) and p53 expression were obtained
from our files [2] (Table 1). MVD was 49.62 ± 33.98%
(median 41%, range 0–160). P53 expression showed a
mean value of 39.15 ± 27.62% (median 35%, range 0–
92%). Tumor hypoxia was also known in all patients.
Mean tumor hypoxic fraction <2.5 mmHg (HF 2.5) values
were 35.89 ± 26.80 (median 35.20%, range 0–91.30%).
MVP expression was independent of clinical and histolog-
ical variables, except for adenocarcinoma tumors. In fact
adenocarcinoma tumors (5 cases) included in the present
study over-expressed MVP versus 15 out of 38 squamous
cancers (p = 0.011). Besides, high MVP expression was
related to severe hypoxia as determined by higher hypoxic
fractions HF (2.5) (45.82 ± 28.00%) compared to low
MVP expressing tumors (27.26 ± 22.96%) (p = 0.022)
(Figure 2a). Tumors over-expressing MVP also showed
increased angiogenesis (65.41 ± 38.38) compared to low
expressing cases (35.89 ± 22.55) (p = 0.003) (Figure 2b).
MVP expression was independent of p53 protein expres-
sion.Radiation Oncology 2009, 4:29 http://www.ro-journal.com/content/4/1/29
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Discussion
In this study we show for the first time that severe tumor
hypoxia is related to high MVP expression in clinical cer-
vical tumors. MVP is ubiquitously expressed and, besides
chemotherapy resistance, it has been implicated in the
regulation of several cellular processes including transport
mechanisms, signal transmissions and immune responses
[13]. Previous studies have demonstrated that vaults are
up-regulated in different multidrug resistant cancer cell
lines [14] and resistance models [15,16]. Increased levels
of MVP have been reported in numerous cell lines after
selection with a wide panel of cytostatic drugs (e.g. doxo-
rubicin, methotrexate, vincristine or cisplatin) [17]. By
contrast, tumour necrosis factor-either applied externally
or after gene transduction, led to down-regulation of MVP
transcription [18]. There are several publications concern-
ing to the relationship between MVP expression and drug
resistance in clinical oncology [19-22]. The role of MVP in
clinical outcome after radio-chemotherapy in cervical car-
cinoma [11] and other cancers [23] has been reported.
MVP seems to down-regulate the pro-apoptotic gene BAX
through its relation with Ku70/80. Ku70/80 are key genes
in the NHEJ repair pathway for radiation-induced DNA
double strand breaks. Expression of Ku70/80 has been
related to survival in patients treated with x-rays [24,25].
Ku70/80 is a central regulator of apoptosis by interacting
with BAX [26] and BCL-2, which in turn has been shown
to suppress Ku, thus inhibiting NHEJ repair [27]. In the
clinical setting, up-regulation of MVP by hypoxia is of crit-
ical relevance because chemotherapy is currently a stand-
ard treatment for those patients. In the other hand,
hypoxia inhibits the NHEJ DNA repair through down-reg-
Table 1: Characteristics of the patients in the study
Characteristics All patients
(n = 43)
MVP low
(n = 23)
MVP high
(n = 20)
P value
Age 49.48 ± 12.79 49.47 ± 13.68 49.50 ± 12.04
(29–81) (29–81) (32–72) 0.325
Stage
I1 4 5 9
II 22 13 9
III 7 5 2 0.228
Histology
E p i d e r m o i d 3 82 31 5
Adenocarcinoma 5 0 5 0.011
Grade
I 532
II 19 10 9
III 19 10 9 0.952
p53 39.15 ± 27.62 37.53 ± 28.04 41.02 ± 27.74
(0–92) (0–92) (0–81) 0.685
Vascular density 49.62 ± 33.98 35.89 ± 22.55 65.41 ± 38.38
(0–160) (0–113) (12–160) 0.003
Hypoxic fraction 35.89 ± 26.80 27.26 ± 22.96 45.82 ± 28.00
(0–91.30) (0–66.30) (0–91.30) 0.022
Median pO2 7.61 ± 8.98 7.84 ± 7.85 7.36 ± 10.34
(0–41.90) (0–24.30) (0–41.90) 0.863
Mean ± standard deviation and range are included as well as p53, vascular density, hypoxic fraction and median of pO2
Representative immunostaining of MVP (a), p53 (b) and micro-vessels (c) Figure 1
Representative immunostaining of MVP (a), p53 (b) and micro-vessels (c).Radiation Oncology 2009, 4:29 http://www.ro-journal.com/content/4/1/29
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ulating Ku70/80 expression [2]. Preclinical studies about
the role of hypoxia in cancer cells showed that reduction
of pO2 is a favoring factor to increase chemo-resistance
[8,28]. In cancer, hypoxia is an adverse prognostic indica-
tor associated with tumor progression and resistance to
therapy [29]. Cellular drug delivery and uptake in hypoxic
areas are affected by hypoxia. Some chemotherapeutic
drugs require oxygen to generate free radicals that contrib-
ute to cytotoxicity. Hypoxia induces cellular adaptations
that compromise the effectiveness of chemotherapy.
Moreover, the expression of several genes controlling
tumor cell survival is regulated by hypoxia (e.g., growth
factors governing the formation of new blood vessels and
hypoxia-responsive transcription factors modulating the
expression of genes). The transcription factor Hypoxia-
inducible factor 1 (HIF-1) is one of the principal media-
tors of homeostasis in human tissues exposed to hypoxia.
It is implicated in virtually every process of rapid gene
expression in response to low oxygen levels [30]. HIF-
1alpha is over-expressed in the majority of common
human cancers and their metastases, due to the presence
of intratumoral hypoxia and as a result of mutations in
genes encoding oncoproteins and tumor suppressor genes
[31,32]. Whether in clinical tumors this chemo-resistance
can be reverted by HIF-1 inhibitors deserves to be studied
[9]. Pharmacologic manipulation of HIF-1 levels may pro-
vide a novel therapeutic approach to diseases like cancer,
especially in combination with anti-angiogenic agents
[33] that would further reduce tumour oxygenation. Our
previously clinical results showed a close relation of clini-
cal hypoxia to increased angiogenesis and in a lesser
extent to p53 oncoprotein alteration [2]. Clinical outcome
in patients suffering different types of tumours mainly
treated by radiation (i.e., cervical and head & neck can-
cers) depends, at least in part, of those parameters. An
increased genetic instability, oncogenic properties, resist-
ance to treatment and increased ability to metastization
are expected.
From our results it could be suggested that hypoxia not
only induces increased genetic instability, oncogenic
properties and metastatization, but through the correla-
tion observed with MVP expression, another pathway of
chemo-resistance could be developed.
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